Francesco Scalabrì
25 works · 561 citations · h-index 10
Top works
- Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome
- Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
- Glycosphingolipid metabolic reprogramming drives neural differentiation
- Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
- X inactivation and reactivation in X-linked diseases
- Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
- MeCP2 as a genome-wide modulator: the renewal of an old story
- 6-Bromoindirubin-3′-oxime intercepts GSK3 signaling to promote and enhance skeletal muscle differentiation affecting miR-206 expression in mice
- Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome
- Dysregulation of the Expression of Asparagine-Linked Glycosylation 13 Short Isoform 2 Affects Nephrin Function by Altering Its N-Linked Glycosylation
- Effects of Mecp2 loss of function in embryonic cortical neurons: a bioinformatics strategy to sort out non-neuronal cells variability from transcriptome profiling
- Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptors
- Scavenger Receptor B1 oxidative post-translational modifications are responsible for its loss in Rett syndrome
- Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
- Abstract 4773: AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL
- MECP2: A Multifunctional Protein Supporting Brain Complexity
- B37 Aberrant sphingosine-1-phosphate metabolism as druggable target in huntington’s disease
- Publisher Correction: 6-Bromoindirubin-3′-oxime intercepts GSK3 signaling to promote and enhance skeletal muscle differentiation affecting miR-206 expression in mice
- Abstract 2610: Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL
- Brain SRB1 modulation as a possible player in Rett syndrome pathogenesis